Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway

被引:37
作者
Kim, Song-Jung [1 ,3 ]
Abdellatif, Maha [4 ]
Koul, Sharat [1 ]
Crystal, George J. [1 ,2 ,3 ]
机构
[1] Univ Illinois, Cardiac Physiol Res Lab, Cardiol Sect, AIMMC, Chicago, IL 60657 USA
[2] Univ Illinois, Dept Anesthesiol, Advocate Illinois Mason Med Ctr, Chicago, IL 60657 USA
[3] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60657 USA
[4] Univ Med & Dent New Jersey, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2008年 / 295卷 / 01期
关键词
myocardial contractility; sarco(endo)plasmic reticulum Ca2+-ATPase 2a;
D O I
10.1152/ajpheart.00298.2008
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Chronic treatment with insulin-like growth factor I (IGF-I) improves contractile function in congestive heart failure and ischemic cardiomyopathy. The present study investigated the effect of chronic treatment with IGF-I on intrinsic myocyte function and the role of the phosphatidylinositol (PI) 3-kinase-Akt- sarco(endo) plasmic reticulum Ca2+-ATPase (SERCA) 2a signaling cascade in these responses. Myocytes were isolated from 23 adult rats and cultured with and without IGF-I (10(-6) M). After 48 h of treatment, myocyte function was evaluated. IGF-I increased contractile function (percent contraction, 7.7 +/- 0.3% vs. 4.5 +/- 0.3%; P < 0.01) and accelerated relaxation time (time for 70% relengthening, 81 +/- 4 vs. 106 +/- 5 ms; P < 0.05) compared with untreated myocytes [control (Con)]. The enhanced function was associated with an increase in Ca2+ transients assessed by fura-2 (340/380 nm; IGF-I, 0.42 +/- 0.02 vs. Con, 0.25 +/- 0.01; P < 0.01). The PI3-kinase inhibitor LY-249002 (10(-9) M) abolished the enhanced function caused by IGF-I. IGF-I increased both Akt and SERCA2a protein levels 2.5-and 4.8-fold, respectively, compared with those of Con (P < 0.01); neither phospholamban nor calsequestrin was affected. To evaluate whether the SERCA2a protein was directly mediated by Akt-SERCA2a signaling, IGF-I-induced changes in the SERCA2a protein were compared in myocytes transfected with adenovirus harboring either constitutively active Akt [multiplicity of infection (MOI), 15] or dominant negative Akt (dnAkt; MOI, 15). The ability of IGF-I to upregulate the SERCA2a protein in myocytes transected with active Akt was absent in dnAkt myocytes. Taken together, our findings indicate that chronic treatment with IGF-I enhances intrinsic myocyte function and that this effect is due to an enhancement in intracellular Ca2+ handling, secondary to the activation of the PI3-kinase-Akt-SERCA2a signaling cascade.
引用
收藏
页码:H130 / H135
页数:6
相关论文
共 38 条
[1]
Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].
Brunet, A ;
Bonni, A ;
Zigmond, MJ ;
Lin, MZ ;
Juo, P ;
Hu, LS ;
Anderson, MJ ;
Arden, KC ;
Blenis, J ;
Greenberg, ME .
CELL, 1999, 96 (06) :857-868
[2]
Regulation of cell death protease caspase-9 by phosphorylation [J].
Cardone, MH ;
Roy, N ;
Stennicke, HR ;
Salvesen, GS ;
Franke, TF ;
Stanbridge, E ;
Frisch, S ;
Reed, JC .
SCIENCE, 1998, 282 (5392) :1318-1321
[3]
Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway -: Studies in rat and ferret isolated muscles [J].
Cittadini, A ;
Ishiguro, Y ;
Strömer, H ;
Spindler, M ;
Moses, AC ;
Clark, R ;
Douglas, PS ;
Ingwall, JS ;
Morgan, JP .
CIRCULATION RESEARCH, 1998, 83 (01) :50-59
[4]
IMPAIRED CARDIAC-PERFORMANCE IN GH-DEFICIENT ADULTS AND ITS IMPROVEMENT AFTER GH REPLACEMENT [J].
CITTADINI, A ;
CUOCOLO, A ;
MEROLA, B ;
FAZIO, S ;
SABATINI, D ;
NICOLAI, E ;
COLAO, A ;
LONGOBARDI, S ;
LOMBARDI, G ;
SACCA, L .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 267 (02) :E219-E225
[5]
Coffer PJ, 1998, BIOCHEM J, V335, P1
[6]
RECOMBINANT HUMAN INSULIN-LIKE GROWTH-FACTOR-I INCREASES FOREARM BLOOD-FLOW [J].
COPELAND, KC ;
NAIR, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (01) :230-232
[7]
Cardiovascular and metabolic effects of insulin-like growth factor I at rest and during exercise in humans [J].
Donath, MY ;
Jenni, R ;
Brunner, HP ;
Anrig, M ;
Kohli, S ;
Glatz, Y ;
Froesch, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (11) :4089-4094
[8]
Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure [J].
Donath, MY ;
Sütsch, G ;
Yan, XW ;
Piva, B ;
Brunner, HP ;
Glatz, Y ;
Zapf, J ;
Follath, F ;
Froesch, ER ;
Kiowski, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) :3177-3183
[9]
INSULIN-LIKE GROWTH-FACTOR-I ENHANCES VENTRICULAR HYPERTROPHY AND FUNCTION DURING THE ONSET OF EXPERIMENTAL CARDIAC-FAILURE [J].
DUERR, RL ;
HUANG, S ;
MIRALIAKBAR, HR ;
CLARK, R ;
CHIEN, KR ;
ROSS, J .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (02) :619-627
[10]
A preliminary study of growth hormone in the treatment of dilated cardiomyopathy [J].
Fazio, S ;
Sabatini, D ;
Capaldo, B ;
Vigorito, C ;
Giordano, A ;
Guida, R ;
Pardo, F ;
Biondi, B ;
Sacca, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (13) :809-814